Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ESG Ratings
PPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Piramal Pharma has disclosed that SES ESG Research Pvt. Ltd has assigned it an ESG rating of 68.5 for FY 2024-25. The rating was based on publicly available data disclosed by the company, and importantly, Piramal Pharma did not engage or commission SES ESG for this rating — SES ESG voluntarily prepared it using the company's own reported ESG information. The disclosure has been made under SEBI Listing Regulations and uploaded on the company's website. The filing was signed by the Interim Company Secretary on March 20, 2026.
A rating of 68.5 is a moderately strong ESG score, which could be viewed positively by sustainability-focused investors and improve the company's standing in ESG-linked funds. Since the rating was unsolicited and based only on public disclosures, it carries limited weight as a commissioned assessment but still serves as an independent benchmark of the company's ESG practices.